BusinessWeek: January 10, 2000

Get Four
Free Issues

Subscribe to BW
Customer Service
ONLINE FEATURES Book Reviews BW Video Columnists Interactive Gallery Newsletters Past Covers Philanthropy Podcasts Special Reports BLOGS Auto Beat Bangalore Tigers Blogspotting Brand New Day Byte of the Apple Economics Unbound Eye on Asia Fine On Media Green Biz Hot Property Investing Insights Management IQ NEXT: Innovation NussbaumOnDesign Tech Beat Working Parents TECHNOLOGY J.D. Power Ratings Product Reviews Tech Stats Wildstrom: Tech Maven AUTOS Home Page Auto Reviews Classic Cars Car Care & Safety Hybrids INNOVATION
& DESIGN Home Page Architecture Brand Equity Auto Design Game Room SMALLBIZ Smart Answers Success Stories Today's Tip INVESTING Investing: Europe Annual Reports BW 50 S&P Picks & Pans Stock Screeners Free S&P Stock Report SCOREBOARDS Hot Growth 100 Mutual Funds Info Tech 100 S&P 500 B-SCHOOLS Undergrad Programs MBA Blogs MBA Profiles MBA Rankings Who's Hiring Grads

BusinessWeek Investor -- Inside Wall Street

Gene Logic May Be Splicing a Deal

  Related Items
Gene Logic May Be Splicing a Deal

CHART: In Line for a Partner?


Is there some logic behind the sudden rush in Gene Logic (GLGC), whose shares have shot up from 3 7/16 in late June to 22 by Dec. 28? Part of the jump stems from investors' discovery of the promise of genomics and the few players in the field. In the case of Gene Logic, which is building a massive database of gene profiles from human and animal tissues, an added factor was speculation that the company was to sign a major deal with at least one drug company--the first partnership for its GeneExpress database. The database carries gene profiles of tissues that have been treated with a variety of compounds to study how they can be targeted by drugs.

Gene Logic is in final talks with three companies that subscribe to GeneExpress, all of which should be completed by the end of the first quarter, says Robertson Stephens analyst Michael King. Some money managers believe Pharmacia & Upjohn may partner with Gene Logic. Gene Logic CEO Michael Brennan confirms that talks are "in their final stages" with three companies, but he wouldn't name them.

The company's goal is to help hasten the discovery of drugs for specific diseases by providing drugmakers with vital gene information. It uses the powerful GeneChip technology of Affymetrix in creating its database. Since Affymetrix, which makes chips for studying DNA, and Gene Logic work closely together, merger speculation has swirled. Trading at 160 a share, Affymetrix has a market value of $4.1 billion. Brennan declined comment on the talk.

King expects Gene Logic to post revenues of $36 million in 2000 and $47.5 million in 2001, vs. 1999's $18.5 million. He sees the company becoming profitable in 2002.

By Gene G. Marcial

Return to top





Return to top
TODAY'S MOST POPULAR STORIES

  1. Jim Rogers on Why Gold Is Glittering So Brightly
  2. Look Who's Stalking Wal-Mart
  3. 'The Sheikh's New Clothes?' Dubai's Desert Dream Ends
  4. Amazon Paces Holiday Tech Discount Drive
  5. Old Navy May Still Be at Sea

Get Free RSS Feed >>
  MARKET INFO
DJIA 10309.92 -154.48
S&P 500 1087.27 -23.36
Nasdaq 2138.44 -37.61

Portfolio Service Update

Stock Lookup

Enter name or ticker



 




Copyright 1991-2009 by The McGraw-Hill Companies Inc. All rights reserved.
Terms of Use | Privacy Notice